A β-Peptide Agonist of the GLP-1 Receptor, a Class B GPCR
作者： Elizabeth V. Denton , Cody J. Craig , Rebecca L. Pongratz , Jacob S. Appelbaum , Amy E. Doerner
DOI: 10.1021/OL402568J
关键词:
摘要: Previous work has shown that certain β3-peptides can effectively mimic the side chain display of an α-helix and inhibit interactions between proteins, both in vitro cultured cells. Here we describe a β3-peptide analog GLP-1, CC-3Act, interacts with GLP-1R extracellular domain (nGLP-1R) manner competes exendin-4 induces GLP-1R-dependent cAMP signaling CHO-K1 cells expressing GLP-1R.
acs.org
core.ac.uk
sci-hub.se 参考文章(42)
K. Adelhorst, B.B. Hedegaard, L.B. Knudsen, O. Kirk, Structure-activity studies of glucagon-like peptide-1. Journal of Biological Chemistry. ,vol. 269, pp. 6275- 6278 ,(1994) , 10.1016/S0021-9258(17)37366-0
R Göke, Hans-Christoph Fehmann, T Linn, Harald Schmidt, Michael Krause, J Eng, B Göke, None, Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. Journal of Biological Chemistry. ,vol. 268, pp. 19650- 19655 ,(1993) , 10.1016/S0021-9258(19)36565-2
Julie A. Lovshin, Daniel J. Drucker, Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology. ,vol. 5, pp. 262- 269 ,(2009) , 10.1038/NRENDO.2009.48
Suleiman Al-Sabah, Dan Donnelly, A model for receptor–peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors British Journal of Pharmacology. ,vol. 140, pp. 339- 346 ,(2003) , 10.1038/SJ.BJP.0705453
William L. Jorgensen, Julian Tirado-Rives, Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. Journal of Computational Chemistry. ,vol. 26, pp. 1689- 1700 ,(2005) , 10.1002/JCC.20297
Arjel D. Bautista, Jacob S. Appelbaum, Cody J. Craig, Julien Michel, Alanna Schepartz, Bridged β3-Peptide Inhibitors of p53-hDM2 Complexation: Correlation between Affinity and Cell Permeability Journal of the American Chemical Society. ,vol. 132, pp. 2904- 2906 ,(2010) , 10.1021/JA910715U
Francis S. Willard, Kyle W. Sloop, Physiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor Experimental Diabetes Research. ,vol. 2012, pp. 470851- 470851 ,(2012) , 10.1155/2012/470851
Dieter Seebach, Mark Overhand, Florian N. M. Kühnle, Bruno Martinoni, Lukas Oberer, Ulrich Hommel, Hans Widmer, β-Peptides: Synthesis by Arndt-Eistert homologation with concomitant peptide coupling. Structure determination by NMR and CD spectroscopy and by X-ray crystallography. Helical secondary structure of a β-hexapeptide in solution and its stability towards pepsin Helvetica Chimica Acta. ,vol. 79, pp. 913- 941 ,(1996) , 10.1002/HLCA.19960790402
Joshua A. Kritzer, James D. Lear, Michael E. Hodsdon, Alanna Schepartz, Helical beta-peptide inhibitors of the p53-hDM2 interaction. Journal of the American Chemical Society. ,vol. 126, pp. 9468- 9469 ,(2004) , 10.1021/JA031625A
Francis S. Willard, Ana B. Bueno, Kyle W. Sloop, Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor Experimental Diabetes Research. ,vol. 2012, pp. 709893- 709893 ,(2012) , 10.1155/2012/709893